These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
217 related articles for article (PubMed ID: 28777443)
1. Use of Human Pluripotent Stem Cell Derived-Cardiomyocytes to Study Drug-Induced Cardiotoxicity. Maillet A; Tan KP; Brunham LR Curr Protoc Toxicol; 2017 Aug; 73():22.5.1-22.5.22. PubMed ID: 28777443 [TBL] [Abstract][Full Text] [Related]
3. Advancing Cardiovascular Drug Screening Using Human Pluripotent Stem Cell-Derived Cardiomyocytes. Oh J; Kwon OB; Park SW; Kim JW; Lee H; Kim YK; Choi EJ; Jung H; Choi DK; Oh BJ; Min SH Int J Mol Sci; 2024 Jul; 25(14):. PubMed ID: 39063213 [TBL] [Abstract][Full Text] [Related]
4. Maturation of Pluripotent Stem Cell-Derived Cardiomyocytes: a Critical Step for Drug Development and Cell Therapy. Tan SH; Ye L J Cardiovasc Transl Res; 2018 Oct; 11(5):375-392. PubMed ID: 29557052 [TBL] [Abstract][Full Text] [Related]
5. Cell death mechanisms of the anti-cancer drug etoposide on human cardiomyocytes isolated from pluripotent stem cells. Nemade H; Chaudhari U; Acharya A; Hescheler J; Hengstler JG; Papadopoulos S; Sachinidis A Arch Toxicol; 2018 Apr; 92(4):1507-1524. PubMed ID: 29397400 [TBL] [Abstract][Full Text] [Related]
6. Modelling cadmium-induced cardiotoxicity using human pluripotent stem cell-derived cardiomyocytes. Shen J; Wang X; Zhou D; Li T; Tang L; Gong T; Su J; Liang P J Cell Mol Med; 2018 Sep; 22(9):4221-4235. PubMed ID: 29993192 [TBL] [Abstract][Full Text] [Related]
7. Functional improvement and maturation of human cardiomyocytes derived from human pluripotent stem cells by barbaloin preconditioning. Yang H; Zhong W; Hamidi MR; Zhou G; Liu C Acta Biochim Biophys Sin (Shanghai); 2019 Sep; 51(10):1041-1048. PubMed ID: 31518384 [TBL] [Abstract][Full Text] [Related]
8. Cardiomyocytes from human pluripotent stem cells: From laboratory curiosity to industrial biomedical platform. Denning C; Borgdorff V; Crutchley J; Firth KS; George V; Kalra S; Kondrashov A; Hoang MD; Mosqueira D; Patel A; Prodanov L; Rajamohan D; Skarnes WC; Smith JG; Young LE Biochim Biophys Acta; 2016 Jul; 1863(7 Pt B):1728-48. PubMed ID: 26524115 [TBL] [Abstract][Full Text] [Related]
9. CRISPR/Cas9-mediated genome editing in human stem cell-derived cardiomyocytes: Applications for cardiovascular disease modelling and cardiotoxicity screening. Christidi E; Huang HM; Brunham LR Drug Discov Today Technol; 2018 Aug; 28():13-21. PubMed ID: 30205876 [TBL] [Abstract][Full Text] [Related]
10. Probing flecainide block of I Geng L; Kong CW; Wong AOT; Shum AM; Chow MZY; Che H; Zhang C; Yau KL; Chan CW; Keung W; Li RA Toxicol Lett; 2018 Sep; 294():61-72. PubMed ID: 29758359 [TBL] [Abstract][Full Text] [Related]
11. Developmental cues for the maturation of metabolic, electrophysiological and calcium handling properties of human pluripotent stem cell-derived cardiomyocytes. Keung W; Boheler KR; Li RA Stem Cell Res Ther; 2014 Jan; 5(1):17. PubMed ID: 24467782 [TBL] [Abstract][Full Text] [Related]
12. High-Content Electrophysiological Analysis of Human Pluripotent Stem Cell-Derived Cardiomyocytes (hPSC-CMs). Kong CW; Geng L; Li RA Methods Mol Biol; 2018; 1722():185-194. PubMed ID: 29264806 [TBL] [Abstract][Full Text] [Related]
13. Moving beyond the comprehensive in vitro proarrhythmia assay: Use of human-induced pluripotent stem cell-derived cardiomyocytes to assess contractile effects associated with drug-induced structural cardiotoxicity. Yang X; Papoian T J Appl Toxicol; 2018 Sep; 38(9):1166-1176. PubMed ID: 29484688 [TBL] [Abstract][Full Text] [Related]
14. Cardiotoxicity evaluation using human embryonic stem cells and induced pluripotent stem cell-derived cardiomyocytes. Zhao Q; Wang X; Wang S; Song Z; Wang J; Ma J Stem Cell Res Ther; 2017 Mar; 8(1):54. PubMed ID: 28279214 [TBL] [Abstract][Full Text] [Related]
15. Identification of genomic biomarkers for anthracycline-induced cardiotoxicity in human iPSC-derived cardiomyocytes: an in vitro repeated exposure toxicity approach for safety assessment. Chaudhari U; Nemade H; Wagh V; Gaspar JA; Ellis JK; Srinivasan SP; Spitkovski D; Nguemo F; Louisse J; Bremer S; Hescheler J; Keun HC; Hengstler JG; Sachinidis A Arch Toxicol; 2016 Nov; 90(11):2763-2777. PubMed ID: 26537877 [TBL] [Abstract][Full Text] [Related]
16. Doxorubicin-induced cardiotoxicity is maturation dependent due to the shift from topoisomerase IIα to IIβ in human stem cell derived cardiomyocytes. Cui N; Wu F; Lu WJ; Bai R; Ke B; Liu T; Li L; Lan F; Cui M J Cell Mol Med; 2019 Jul; 23(7):4627-4639. PubMed ID: 31106979 [TBL] [Abstract][Full Text] [Related]
18. Promotion of maturation of human pluripotent stem cell-derived cardiomyocytes via treatment with the peroxisome proliferator-activated receptor alpha agonist Fenofibrate. Lee SG; Rhee J; Seok J; Kim J; Kim MW; Song GE; Park S; Jeong KS; Lee S; Lee YH; Jeong Y; Kim CY; Chung HM Stem Cells Transl Med; 2024 Aug; 13(8):750-762. PubMed ID: 38946019 [TBL] [Abstract][Full Text] [Related]
19. Characterization of human-induced pluripotent stem cell-derived cardiomyocytes: bioenergetics and utilization in safety screening. Rana P; Anson B; Engle S; Will Y Toxicol Sci; 2012 Nov; 130(1):117-31. PubMed ID: 22843568 [TBL] [Abstract][Full Text] [Related]
20. Single-Cell Mechanical Analysis of Human Pluripotent Stem Cell-Derived Cardiomyocytes for Drug Testing and Pathophysiological Studies. Ballan N; Shaheen N; Keller GM; Gepstein L Stem Cell Reports; 2020 Sep; 15(3):587-596. PubMed ID: 32763158 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]